Fluidigm Announces Third Quarter 2020 Financial Results
November 05, 2020 16:05 ET
|
Fluidigm Corporation
Third Quarter Total Revenue Increased 50 Percent to $39.9 Million Third Quarter Product and Service Revenue Increased 34 Percent to $35.3 Million Driven by COVID-19 Testing GAAP Net Loss in the...
Fluidigm Announces Second Quarter 2020 Financial Results
August 06, 2020 16:05 ET
|
Fluidigm Corporation
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
Fluidigm to Present at Upcoming Health Care Investor Conferences
May 13, 2020 16:02 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces First Quarter 2020 Financial Results
May 07, 2020 16:05 ET
|
Fluidigm Corporation
First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for...
Fluidigm Receives Life Science Industry Award for the Maxpar Direct Immune Profiling System
December 09, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioInformatics Inc., the leading research and advisory firm serving the life science tools market, recognized Fluidigm...
Fluidigm Drives a New Standard in Human Immune Profiling
November 05, 2019 16:02 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced it has exceeded $1 million in revenue from its industry-leading Maxpar® Direct™...
Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring
January 08, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif. and MONTREAL, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory providing state-of-the-art...
Fluidigm to Participate at Upcoming Investor Events in September
September 05, 2018 18:00 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s...
Fluidigm Announces Second Quarter 2018 Financial Results
August 02, 2018 16:05 ET
|
Fluidigm Corporation
Total revenue increases 11 percent to $26.4 million Mass cytometry revenue growth of 32 percent Total consumables revenue growth of 19 percent SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE...
Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical Research
April 13, 2018 16:10 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Maxpar® Human Immune Monitoring Panel Kit for comprehensive...